These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33903060)

  • 1. The use of an integrated opioid and medical marijuana prescription drug monitoring program.
    Rickles NM; Wakai S; Karim-Nejad L
    J Am Pharm Assoc (2003); 2021; 61(4):408-417. PubMed ID: 33903060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacists' Perspectives on Practice, Availability, and Barriers Related to Opioids in Georgia.
    Lal A; Bai J; Basri D; Yeager KA
    Am J Hosp Palliat Care; 2019 Jun; 36(6):472-477. PubMed ID: 30522338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survey of Pharmacists' Knowledge of Connecticut's Medical Cannabis Program.
    Reece SM; Holle L; Mukherjee K
    Cannabis Cannabinoid Res; 2021; 6(1):66-73. PubMed ID: 33614954
    [No Abstract]   [Full Text] [Related]  

  • 7. How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment.
    Picco L; Sanfilippo P; Xia T; Lam T; Nielsen S
    Int J Drug Policy; 2022 Nov; 109():103856. PubMed ID: 36150356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Reported Marijuana Use Is Associated with Increased Use of Prescription Opioids Following Traumatic Musculoskeletal Injury.
    Bhashyam AR; Heng M; Harris MB; Vrahas MS; Weaver MJ
    J Bone Joint Surg Am; 2018 Dec; 100(24):2095-2102. PubMed ID: 30562289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacist Opioid Dispensing Confidence in an Evolving Practice Landscape.
    Herndon CM; Riley AM; Gattas NM; Tiemeier AM
    J Pain Palliat Care Pharmacother; 2022 Sep; 36(3):187-193. PubMed ID: 35975957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of US Medical Marijuana Laws With Nonmedical Prescription Opioid Use and Prescription Opioid Use Disorder.
    Segura LE; Mauro CM; Levy NS; Khauli N; Philbin MM; Mauro PM; Martins SS
    JAMA Netw Open; 2019 Jul; 2(7):e197216. PubMed ID: 31314118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients.
    Riley TB; Alemagno S
    Res Social Adm Pharm; 2019 Aug; 15(8):986-991. PubMed ID: 30665825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists.
    Alley L; Novak K; Havlin T; Irwin AN; Carson J; Johnston K; O'Kane N; Hartung DM
    Res Social Adm Pharm; 2020 Oct; 16(10):1422-1430. PubMed ID: 31953112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist Views Regarding the Prescription Opioid Epidemic.
    Rao D; Giannetti V; Kamal KM; Covvey JR; Tomko JR
    Subst Use Misuse; 2021; 56(14):2096-2105. PubMed ID: 34429024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.
    Alvin M; Picco L; Wood P; Mnatzaganian G; Nielsen S
    Int J Clin Pharm; 2021 Apr; 43(2):411-419. PubMed ID: 32951182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of Patient Opioid Use Reporting at the Time of Medical Cannabis License Renewal.
    Vigil JM; Stith SS; Reeve AP
    Pain Res Manag; 2018; 2018():5704128. PubMed ID: 29623144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.